Last month, California Governor signed the most comprehensive drug pricing transparency bill in the nation. SB-17 is intended to promote transparency in drug pricing, reduce overall healthcare spending, and shine light on how drugs are priced. Under the new law, drug manufacturers, PBMs, health plans, and insurers operating in California are required to report drug
Drug Pricing
States take drug price gorging into their own hands
By Natalia Mazina on
Posted in Drug Pricing
Unlike most countries, the U.S. does not regulate drug pricing but allows the market to set them according to demand. On numerous occasions, the U.S. Congress sided with the pharmaceutical industry and failed to pass laws that would change how drugs are priced. In addition, the Trump administration has delayed the implementation of a rule…
Biosimilars – effect on specialty pharmacy
By Natalia Mazina on
Biologics are the fastest growing and the most expensive class of drugs on the market. The current cost of biologics is between $50,000 to $250,000 for one year of treatment. FTC Press Release. The numbers are expected to increase even further. Congressional Research.
Biosimilars –on the other hand – are less expensive due…